Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaVitaSTU:TRL -14.67%84 Receivables Turnover is 1.45 as of Jun. 2026. GuruFocus rates STU:TRL with a GF Score™ of 84/100 and a GF Value™ of €166.64 (Fairly Valued). The stock has 4 warning signs investors should review. Among 658 Healthcare Providers & Services companies, DaVita ranks worse than 66.72% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. DaVita's Revenue for the
three
months ended in Jun. 2026 was €3,085 Mil. DaVita's average Accounts Receivable for the
three
months ended in Jun. 2026 was €2,134 Mil.
Hence, DaVita's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.45.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
DaVita Receivables Turnover Related Terms
DaVita Receivables Turnover Historical Data
* Premium members only.
The historical data trend for DaVita's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:TRL vs EHC, THC, ENSG: Receivables Turnover Comparison
For the Medical Care Facilities subindustry, DaVita's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where DaVita's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaVita (STU:TRL) has a Receivables Turnover of 1.45 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DaVita and its competitors. According to the industry distribution chart, DaVita ranks #439 out of 658 companies in the Healthcare Providers & Services industry, placing it in the top 66.7%.
Is DaVita's Receivables Turnover too high?
DaVita's current Receivables Turnover is 1.45. The Healthcare Providers & Services industry median Receivables Turnover is 7.80. DaVita's value of 1.45 is 81.4% below this industry median. Based on the distribution chart, DaVita ranks #439 out of 658 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, DaVita has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaVita's Receivables Turnover compare to EHC and THC?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #439 out of 658 companies for Receivables Turnover. This places DaVita in the lower half of its industry. The industry median Receivables Turnover is 7.80. DaVita's value of 1.45 is 81.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.80, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaVita's current Receivables Turnover of 1.45 is 81.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on DaVita and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaVita's current Receivables Turnover is 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (STU:TRL) is currently considered Fairly Valued. The stock's GF Value™ is €166.64, compared to a current price of €155.85 — trading 6.5% below its estimated fair value. The current Receivables Turnover is 1.45 and 81.4% below the Healthcare Providers & Services industry median of 7.80. DaVita's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For DaVita (STU:TRL), the current Receivables Turnover is 1.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (STU:TRL) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be undervalued.
The current stock price of €155.85 is trading 6.5% below its estimated GF Value™ of €166.64.
GuruFocus considers DaVita to be Fairly Valued.
Key valuation signals for STU:TRL:
Receivables Turnover: 1.45
GF Value™: €166.64 vs. price of €155.85 (6.5% below fair value)
Industry Position: 81.4% below the Healthcare Providers & Services median (#439 of 658)
No single metric tells the full story. See the STU:TRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
84GF Score
Get the complete analysis for STU:TRL
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TRL has been successfully added to your 
